Liu Erheng, Zhao Heng, Liu Chengyuan, Tan Xueyi, Luo Chao, Yang Shuaifeng
Department of Neurosurgery, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.
Department of Neurosurgery, The First People's Hospital of Yunnan Province, Kunming, China.
Front Surg. 2022 Aug 26;9:969090. doi: 10.3389/fsurg.2022.969090. eCollection 2022.
Moyamoya disease (MMD) is an idiopathic cerebrovascular disease which was first described by Suzuki and Takaku in 1969. Moyamoya disease is a non-atherosclerotic cerebrovascular structural disorder. MMD has been found all over the world, especially in Japan, Korea, and China. In recent years, many reports pointed out that the changes of vascular stenosis in patients with moyamoya disease occurred not only in intracranial vessels, but also in extracranial vessels, especially the changes of renal artery. Renovascular hypertension (RVH) is considered to be one of the important causes of hypertension in patients with moyamoya disease. The pathogenesis of moyamoya disease combined with renovascular hypertension is still unclear, and the selection of treatment has not yet reached a consensus. This article reviews the latest research progress in epidemiology, RNF213 gene, pathomorphology, clinical characteristics and treatment of moyamoya disease combined with renovascular hypertension, in order to provide reference for clinical workers.
烟雾病(MMD)是一种特发性脑血管疾病,于1969年由铃木和高久首次描述。烟雾病是一种非动脉粥样硬化性脑血管结构紊乱疾病。烟雾病在世界各地均有发现,尤其是在日本、韩国和中国。近年来,许多报告指出,烟雾病患者的血管狭窄变化不仅发生在颅内血管,也发生在颅外血管,尤其是肾动脉的变化。肾血管性高血压(RVH)被认为是烟雾病患者高血压的重要病因之一。烟雾病合并肾血管性高血压的发病机制仍不清楚,治疗方案的选择也尚未达成共识。本文综述了烟雾病合并肾血管性高血压在流行病学、RNF213基因、病理形态学、临床特征及治疗方面的最新研究进展,以期为临床工作者提供参考。